Journal of Vascular Surgery
Volume 52, Issue 2 , Pages 369-374 , August 2010

A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass

Presented in part at the Midwestern Vascular Surgery Society Society, Madison, Wisc, September 11-13, 2008.

  • Vikram S. Kashyap, MD

      Affiliations

    • Department of Vascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: Vikram S. Kashyap, MD, Cleveland Clinic, Department of Vascular Surgery, H32, 9500 Euclid Ave., Cleveland, OH 44195
    • ,
  • Paul D. Bishop, MS

      Affiliations

    • Department of Vascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • ,
  • James F. Bena, MS

      Affiliations

    • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Karen Rosa, RN

      Affiliations

    • Department of Vascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Timur P. Sarac, MD

      Affiliations

    • Department of Vascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Kenneth Ouriel, MD

      Affiliations

    • New York Presbyterian Hospital, New York, NY

Received 23 November 2009 ,Accepted 23 February 2010.

References 

  1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–e654
  2. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391
  3. Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J. 2000;139:696–703
  4. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256
  5. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639–643
  6. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8th Edition) Chest. 2008;133(6 Suppl):340S–380S
  7. Calaitges JG, Liem TK, Spadone D, Nichols WK, Silver D. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg. 1999;29:779–785
  8. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506–1511
  9. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA The Advisory Panel. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. J Vasc Interv Radiol. 2000;11(2 Pt 1):149–161
  10. White HD. Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome. Expert Opin Drug Metab Toxicol. 2009;5:529–538
  11. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial–phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11
  12. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82:12P–18P
  13. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J. 2009;30:1831–1836
  14. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952–959
  15. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  16. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696–703
  17. Allie DE, Hall P, Shammas NW, Safian R, Laird JR, Young JJ, et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results. J Invasive Cardiol. 2004;16:651–656
  18. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686–692
  19. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL, Kirshner R, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533–539

 Supported by The Medicines Company.

 Competition of interest: none.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(10)00661-0

doi: 10.1016/j.jvs.2010.02.276

Journal of Vascular Surgery
Volume 52, Issue 2 , Pages 369-374 , August 2010

Article Tools

* Image Usage & Resolution